EGFR and non-small cell lung carcinoma: Typically, in current clinical practice, erlotinib is prescribed to advanced non-small cell lung cancer patients with tumors harboring an EGFR sensitizing mutation, due to its higher likelihood of response rate and lower overall toxicity rate relative to cytotoxic chemotherapy.